{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:58:54Z","timestamp":1775703534254,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2018,6,19]]},"abstract":"\n Background<\/jats:title>\n \n The\n US<\/jats:styled-content>\n Food and Drug Administration approved sacubitril\/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the\n PARADIGM<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angiotensin\u2010Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. There are limited data assessing the generalizability of\n PARADIGM<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n trial participants to a broader population of patients with HF with reduced ejection fraction routinely encountered in outpatient clinical practice.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n We compared the baseline characteristics of patients in the\n PARADIGM<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n trial with those in the\n CHAMP<\/jats:styled-content>\n \u2010HF (Change the Management of Patients With Heart Failure) study a large\n US<\/jats:styled-content>\n outpatient registry of patients with HF with reduced ejection fraction. Patients in the\n PARADIGM<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n trial (n=8442) were similar to those in the\n CHAMP<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n registry (n=3497) in terms of age (mean, 64\u00a0versus 66\u00a0years), sex (22% versus 29% women), New York Heart Association class\n III<\/jats:styled-content>\n to\n IV<\/jats:styled-content>\n (25% versus 32%), systolic blood pressure (mean, 121\u00a0versus 121\u00a0mm\u00a0Hg), left ventricular ejection fraction (mean, 29% versus 29%), and other key baseline characteristics. The median (25th\u201375\n th<\/jats:sup>\n percentile) Meta\u2010Analysis Global Group in Chronic Heart Failure risk scores were similar for the 2 studies (20 [16\u201324] versus 22 [8\u201327]). Despite this, only 13% of patients in the\n CHAMP<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n registry were prescribed sacubitril\/valsartan at baseline.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These data suggest participants randomized in the\n PARADIGM<\/jats:styled-content>\n \u2010\n HF<\/jats:styled-content>\n trial have similar baseline characteristics to those encountered in routine outpatient clinical practice, but there is a substantial lag in the adoption of sacubitril\/valsartan for patients with chronic HF with reduced ejection fraction.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/jaha.118.009237","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T09:15:24Z","timestamp":1528794924000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Characteristics and Treatments of Patients Enrolled in the CHAMP\u2010HF Registry Compared With Patients Enrolled in the PARADIGM\u2010HF Trial"],"prefix":"10.1161","volume":"7","author":[{"given":"Adam D.","family":"DeVore","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"},{"name":"Department of Medicine Duke University School of Medicine Durham NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Mi","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puza P.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy M.","family":"Albert","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"University of Mississippi Medical Center Jackson MS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"},{"name":"Department of Medicine Duke University School of Medicine Durham NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Herbert","family":"Patterson","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy University of North Carolina Chapel Hill NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute and the University of Missouri\u2013Kansas City Kansas City MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredonia B.","family":"Williams","sequence":"additional","affiliation":[{"name":"Mended Hearts Huntsville AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol I.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McCague","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson\u2010UCLA Cardiomyopathy Center Ronald Reagan UCLA Medical Center Los Angeles CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.03.007"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.04.010"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.115"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.878"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs337"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.027773"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.01.004"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12246"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.12.018"},{"key":"e_1_3_1_13_2","volume-title":"Crossing the Quality Chasm: A New Health System for the 21st Century","author":"Institute of Medicine (US) Committee on Quality of Health Care in America","year":"2001","unstructured":"Institute of Medicine (US) Committee on Quality of Health Care in America . Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): The National Academies Press; 2001. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK222274\/doi:10.17226\/10027"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000481"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.118.009237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:27:27Z","timestamp":1715599647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.118.009237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6,19]]}},"alternative-id":["10.1161\/JAHA.118.009237"],"URL":"https:\/\/doi.org\/10.1161\/jaha.118.009237","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"2018-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e009237"}}